Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis

References

• Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36:239–245.
   PubMed Web of Science ®Google Scholar
• Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68:4–7.
   PubMed Web of Science ®Google Scholar
• Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492–501.
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Meyer J, Goff D . Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86;15–22.
   PubMed Web of Science ®Google Scholar
• Daumit GL, Pronovost PJ, Anthony CB, Guallar E, Steinwachs DM, Ford DE. Adverse events during medical and surgical hospitalizations for persons with schizophrenia. Arch Gen Psychiatry 2006; 63:267–272.
   PubMed Web of Science ®Google Scholar
• Álvarez-Jiménez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Hetrick S, Rodriguez-Sanchez JM, Crespo-Facorro B. Antipsychotic-induced weight gain in schizophrenia spectrum disorders: a systematic critical reappraisal. CNS Drugs 2008; 22:547–562.
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Laimer M, Kaser . Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61:1356–1370.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19:S1–93.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298:1794–1796.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765–1773.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66:51–57.
   PubMed Web of Science ®Google Scholar
• Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106:286–290.
   PubMed Web of Science ®Google Scholar
• Angermeyer MC, Matschisger H. Neuroleptics and quality of life: a patient survey. Psychiatr Prax 2000; 27:64–68.
   PubMed Web of Science ®Google Scholar
• Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004; 65:13–26.
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Gu H, Green AI . Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187:537–543.
   PubMed Web of Science ®Google Scholar
• Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry, 2011; 68:609–616.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163:2072–2079.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL . Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naïve first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67:1253–1260.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193:101–107.
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1:CD005148.
   Google Scholar
• Cohn TA, Sernyak MJ. Metabolic monitoring of patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492–501.
   PubMed Web of Science ®Google Scholar
• Lambert TJR, Chapman LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181:544–548.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM, on behalf of the UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33:1397–1403.
   PubMed Web of Science ®Google Scholar
• Morrato EH, Druss B, Hartung DM . Metabolic testing rates in three state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67:17–24.
   PubMed Web of Science ®Google Scholar
• Walter G, Delaroche A, Soh N . Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry 2008; 16:253–262.
   PubMed Web of Science ®Google Scholar
• Crabb J, McAllister M, Blair A. Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team. Early Interv Psychiatry 2009; 3:312–316.
   PubMed Web of Science ®Google Scholar
• Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001; 39:II–46–II–54.
   Web of Science ®Google Scholar
• Killackey E, Jorm A, Alvarez-Jimenez M, McCann TV, Hides L, Couineau AL. Do we do what we know works, and if not why not? Aust N Z Psychiatry 2008; 42:439–444.
   PubMed Web of Science ®Google Scholar
• Grimshaw JM, Thomas RE, MacLennan G . Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8:iii–iv, 1–72.
   Google Scholar
• Grol R. Personal paper: beliefs and evidence in changing clinical practice. BMJ 1997; 315:418–421.
   PubMed Web of Science ®Google Scholar
• Baker R, Camosso-Stefinovic J, Gillies C, . Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database of Syst Rev 2010; 3:CD005470.
   Google Scholar
• Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009; 32: 1037–1042.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118:26–33.
   PubMed Web of Science ®Google Scholar
• Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190:S39–42.
   PubMed Web of Science ®Google Scholar
• Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009; 190:185–189.
   PubMed Web of Science ®Google Scholar
• Edwards, J, Harris, M, Herman, A. The Early Psychosis Prevention and Intervention Centre Melbourne Australia: An overview November 2001. Ogura C. Recent advances in early intervention and prevention in psychiatric disorders. Tokyo: Seiwa-Shoten, 2002:26–33.
   Google Scholar
• Hetrick S, Alvarez-Jimenez M, Parker A et al. Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic. Australas Psychiatry 2010; 18:451–455.
   PubMed Web of Science ®Google Scholar
• Batscha C, Schneiderhan ME, Kataria Y, Rosen C, Marvin RW. Treatment settings and metabolic monitoring for people experiencing first-episode psychosis. J Psychosoc Nurs Ment Health Serv 2010; 48:44–49.
   PubMed Web of Science ®Google Scholar
• Mackin P, Bishop D, Watkinson H. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007; 7:28.
   PubMed Web of Science ®Google Scholar
• Dunbar L, Wheeler A, Harrison J . Implementing metabolic risk assessment in a secondary care mental health service. Australas Psychiatry 2010; 18:318–321.
   PubMed Web of Science ®Google Scholar
• McGorry P, Tanti C, Stokes R . headspace: Australia's national youth mental health foundation––where young minds come first. Med J Aust 2007; 187:S68–70.
   Web of Science ®Google Scholar
• Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman A. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database of Syst Rev 2006; 2:CD000259.
   Google Scholar
• Foley D, Morley K, Carroll K, Moran J, McGorry P, Murphy B. Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics. Med J Aust 2009; 191:518–519.
   PubMed Web of Science ®Google Scholar